Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
AIDS Clinical Trials Group
ClinicalTrials.gov Identifier:
NCT00830804
First received: January 26, 2009
Last updated: December 7, 2011
Last verified: December 2011
Results First Received: September 7, 2011  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV-1 Infections
Interventions: Drug: Raltegravir
Drug: Darunavir/Ritonavir

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Study participants were recruited from 22 U.S. sites from April 2009 to August 2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Study participants were HIV-1-infected, antiretroviral(ARV)-naive men and women, 18 years and older with plasma HIV-1 RNA >= 5000 copies/ml. One enrolled participant never started study treatment.

Reporting Groups
  Description
RAL + DRV/RTV Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks

Participant Flow:   Overall Study
    RAL + DRV/RTV  
STARTED     112 [1]
COMPLETED     97  
NOT COMPLETED     15  
Lost to Follow-up                 4  
Death                 1  
Unable to get to clinic                 7  
Consent withdrawn                 2  
Unwilling to adhere to study requirement                 1  
[1] 113 subjects enrolled. One subject never started study treatment and was excluded in all analysis.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
RAL+DRV/RTV Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks

Baseline Measures
    RAL+DRV/RTV  
Number of Participants  
[units: participants]
  112  
Age [1]
[units: years]
Median ( Full Range )
  36  
  ( 19 to 66 )  
Age, Customized [1]
[units: participants]
 
18-29     33  
30-39     38  
40-49     25  
50-59     12  
60-69     4  
Gender  
[units: participants]
 
Female     14  
Male     98  
Region of Enrollment  
[units: participants]
 
United States     112  
Puerto Rico     0  
[1] Age (in years) of participants at study entry



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Participants With Virologic Failure After Initiating RAL Plus DRV/RTV at or Prior to Week 24   [ Time Frame: From start of study treatment to week 24 ]

2.  Secondary:   Proportion of Participants With Virologic Failure or Off Study Treatment Regimen or Death at or Prior to Week 24   [ Time Frame: From start of study treatment to Week 24 ]

3.  Secondary:   Change in Plasma HIV-1 RNA From Baseline to Week 1   [ Time Frame: Baseline and week 1 ]

4.  Secondary:   Proportion of Participants With Plasma HIV-1 RNA < 50 Copies/ml or <200 Copies/ml at Week 24   [ Time Frame: From start of study treatment to week 24 ]

5.  Secondary:   Proportion of Participants With Plasma HIV-1 RNA <50 Copies/ml or <200 Copies/ml at Week 48   [ Time Frame: From start of study treatment to week 48 ]

6.  Secondary:   Proportion of Participants Who Experienced Signs/Symptoms or Laboratory Toxicities Grade 3 or Higher, or of Any Grade Which Led to a Permanent Change or Discontinuation of Study Treatment   [ Time Frame: From start of study treatment to week 52 ]

7.  Secondary:   Number of Participants With Pretreatment Drug Resistance   [ Time Frame: At screening ]

8.  Secondary:   Number of Participants With Integrase Drug Resistance at Virologic Failure   [ Time Frame: From 12 weeks after starting study treatment to week 52 ]
  Hide Outcome Measure 8

Measure Type Secondary
Measure Title Number of Participants With Integrase Drug Resistance at Virologic Failure
Measure Description Results report the number of participants who had integrase resistance mutation(s) detected at the time of virologic failure.
Time Frame From 12 weeks after starting study treatment to week 52  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Only those participants who had virologic failure (see primary outcome measure for definition) and who had successful integrase genotyping at failure were included in the analysis.

Reporting Groups
  Description
RAL+DRV/RTV Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks

Measured Values
    RAL+DRV/RTV  
Number of Participants Analyzed  
[units: participants]
  25  
Number of Participants With Integrase Drug Resistance at Virologic Failure  
[units: participants]
  5  

No statistical analysis provided for Number of Participants With Integrase Drug Resistance at Virologic Failure



9.  Secondary:   Number of Participants With Protease Drug Resistance at Virologic Failure   [ Time Frame: From 12 weeks after starting study treatment to week 52 ]

10.  Secondary:   Number of Participants With Perfect Overall Adherence by Self Report   [ Time Frame: From one week after starting study treatment to week 52 ]

11.  Secondary:   Changes in Fasting Total Cholesterol, High-density Lipoprotein and Triglyceride at Week 24   [ Time Frame: From start of study treatment through week 24 ]

12.  Secondary:   Change in Fasting Low-density Lipoprotein at Week 24   [ Time Frame: From start of study treatment through week 24 ]

13.  Secondary:   Changes in Fasting Total Cholesterol, High-density Lipoprotein and Triglyceride at Week 48   [ Time Frame: From start of study treatment through week 48 ]

14.  Secondary:   Change in Fasting Low-density Lipoprotein at Week 48   [ Time Frame: From start of study treatment through week 48 ]

15.  Secondary:   Change in CD4 Count at Week 48   [ Time Frame: From start of study treatment through week 48 ]

16.  Secondary:   Plasma Trough Concentration of Raltegravir   [ Time Frame: From start of study treatment to week 52 ]

17.  Secondary:   Plasma Trough Concentration of Darunavir   [ Time Frame: From start of study treatment to week 52 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
This is a single-arm study.


  More Information